Loading...
Loading...
ONCR| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 15.1M |
| Operating I/L | -0.6M |
| Other Income/Expense | -30.3M |
| Interest Income | 0.0M |
| Pretax | -30.9M |
| Income Tax Expense | 2.4M |
| Net Income/Loss | -33.3M |
Oncorus, Inc. is a clinical-stage biopharmaceutical company specializing in viral immunotherapies for cancer treatment. Their lead product candidate, ONCR-177, is an intratumorally administered viral immunotherapy currently in Phase I clinical trials for various cancers. The company also develops ONCR-GBM, a preclinical stage oHSV program for brain cancer treatment, and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus has a clinical trial collaboration and supply agreement with MSD International GmbH to assess the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in Phase 1 clinical trials for solid tumors.
